BRPI0923231B8 - anticorpo anti-cmet - Google Patents

anticorpo anti-cmet

Info

Publication number
BRPI0923231B8
BRPI0923231B8 BRPI0923231A BRPI0923231A BRPI0923231B8 BR PI0923231 B8 BRPI0923231 B8 BR PI0923231B8 BR PI0923231 A BRPI0923231 A BR PI0923231A BR PI0923231 A BRPI0923231 A BR PI0923231A BR PI0923231 B8 BRPI0923231 B8 BR PI0923231B8
Authority
BR
Brazil
Prior art keywords
antibody
composition
receptor
met
cmet antibody
Prior art date
Application number
BRPI0923231A
Other languages
English (en)
Inventor
Bes Cédric
Goetsch Liliane
Wurch Thierry
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41693124&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0923231(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/IB2008/055663 external-priority patent/WO2010064089A1/en
Application filed by Pf Medicament filed Critical Pf Medicament
Priority to BR122019023930-4A priority Critical patent/BR122019023930B1/pt
Publication of BRPI0923231A2 publication Critical patent/BRPI0923231A2/pt
Publication of BRPI0923231B1 publication Critical patent/BRPI0923231B1/pt
Publication of BRPI0923231B8 publication Critical patent/BRPI0923231B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Connection Of Motors, Electrical Generators, Mechanical Devices, And The Like (AREA)
  • Medicinal Preparation (AREA)

Abstract

anticorpo anti-cmet, seu uso e processo de preparação, ácido nucleico isolado que os codificam, composição que os compreende, vetor e célula hospedeira que o compreende, bem como método de diagnóstico in vitro de doença. a presente invenção refere-se a um anticorpo capaz de se ligar especificamente ao receptor c-met humano e/ou capaz de inibir especificamente a atividade de tirosina cinase do dito receptor, com uma atividade antagonística aperfeiçoada, o dito anticorpo compreendendo uma região de dobre modificada. uma composição compreendendo tal antagonista de anticorpo para c-met e seu uso como um medicamento para tratamento de câncer.
BRPI0923231A 2008-12-02 2009-12-02 anticorpo anti-cmet BRPI0923231B8 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122019023930-4A BR122019023930B1 (pt) 2008-12-02 2009-12-02 Anticorpo anti-cmet, seu uso e processo de preparação, ácido nucleico isolado que o codifica, composição que o compreende, vetor, bem como método de diagnóstico in vitro de doença

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/IB2008/055663 WO2010064089A1 (en) 2008-12-02 2008-12-02 Novel anti-cmet antibody
US18450209P 2009-06-05 2009-06-05
PCT/EP2009/066201 WO2010069765A1 (en) 2008-12-02 2009-12-02 ANTI-cMET ANTIBODY

Publications (3)

Publication Number Publication Date
BRPI0923231A2 BRPI0923231A2 (pt) 2016-01-26
BRPI0923231B1 BRPI0923231B1 (pt) 2020-04-28
BRPI0923231B8 true BRPI0923231B8 (pt) 2021-05-25

Family

ID=41693124

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122019023930-4A BR122019023930B1 (pt) 2008-12-02 2009-12-02 Anticorpo anti-cmet, seu uso e processo de preparação, ácido nucleico isolado que o codifica, composição que o compreende, vetor, bem como método de diagnóstico in vitro de doença
BRPI0923231A BRPI0923231B8 (pt) 2008-12-02 2009-12-02 anticorpo anti-cmet

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122019023930-4A BR122019023930B1 (pt) 2008-12-02 2009-12-02 Anticorpo anti-cmet, seu uso e processo de preparação, ácido nucleico isolado que o codifica, composição que o compreende, vetor, bem como método de diagnóstico in vitro de doença

Country Status (38)

Country Link
US (4) US8741290B2 (pt)
EP (4) EP3431502B1 (pt)
JP (3) JP5863458B2 (pt)
KR (1) KR101838299B1 (pt)
CN (2) CN103351438B (pt)
AR (1) AR074439A1 (pt)
AU (3) AU2009328318C1 (pt)
BR (2) BR122019023930B1 (pt)
CA (1) CA2743433C (pt)
CL (2) CL2011001296A1 (pt)
CO (1) CO6382139A2 (pt)
CR (1) CR20110324A (pt)
CY (2) CY1119172T1 (pt)
DK (2) DK3135691T3 (pt)
EC (1) ECSP11011127A (pt)
ES (3) ES2827277T3 (pt)
GE (2) GEP20135930B (pt)
HR (2) HRP20171011T8 (pt)
HU (3) HUE040553T2 (pt)
IL (2) IL213273A0 (pt)
LT (2) LT2370468T (pt)
MA (1) MA32892B1 (pt)
MX (2) MX2011005677A (pt)
MY (2) MY185200A (pt)
NZ (1) NZ593853A (pt)
PE (1) PE20120343A1 (pt)
PH (1) PH12015501515A1 (pt)
PL (3) PL2370468T3 (pt)
PT (3) PT2370468T (pt)
RS (2) RS56204B1 (pt)
RU (2) RU2015127471A (pt)
SA (2) SA109300720B1 (pt)
SG (2) SG171851A1 (pt)
SI (3) SI3431502T1 (pt)
TN (1) TN2011000216A1 (pt)
TW (2) TWI523866B (pt)
WO (1) WO2010069765A1 (pt)
ZA (1) ZA201105164B (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
EP2287197A1 (en) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
PT3904391T (pt) 2010-03-10 2024-10-14 Genmab As Anticorpos monoclonais contra c-met
KR20140019284A (ko) 2010-09-03 2014-02-14 아카데미아 시니카 항-C-Met 항체 및 이의 이용 방법들
RU2608644C2 (ru) 2010-11-03 2017-01-23 арДЖЕН-ИКС Н.В. Антитела против белка рецептора с-мет
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
KR20130036993A (ko) * 2011-10-05 2013-04-15 삼성전자주식회사 ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
KR101865223B1 (ko) 2011-10-05 2018-06-08 삼성전자주식회사 항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도
US9926364B2 (en) 2011-11-03 2018-03-27 Argen-X N.V. Chimeric human-llama antigens and methods of use
KR101463098B1 (ko) * 2011-11-28 2014-11-27 한국생명공학연구원 ｃ-Ｍｅｔ에 대한 인간항체에 약물이 접합된 약물 복합체 및 이의 용도
US8900582B2 (en) 2011-12-22 2014-12-02 Samsung Electronics Co., Ltd. Deimmunized anti c-Met humanized antibodies and uses thereof
CN105050618B (zh) * 2012-06-21 2018-11-16 索伦托治疗有限公司 与c-Met结合的抗原结合蛋白
EP2708556B1 (en) 2012-09-12 2018-11-07 Samsung Electronics Co., Ltd Pharmaceutical composition for the use in a combination therapy for prevention or treatment of c-met or angiogenesis factor induced diseases
MX338711B (es) 2012-10-12 2016-04-28 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
MX362970B (es) 2013-03-13 2019-02-28 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
KR102049990B1 (ko) * 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
CN105452297B (zh) 2013-04-30 2019-10-11 新加坡科技研究局 mAb 2抗-Met抗体
US9567641B2 (en) * 2013-07-03 2017-02-14 Samsung Electronics Co., Ltd. Combination therapy for the treatment of cancer using an anti-C-met antibody
US9717715B2 (en) 2013-11-15 2017-08-01 Samsung Electronics Co., Ltd. Method of combination therapy using an anti-C-Met antibody
EP3083697B1 (en) * 2013-12-20 2019-04-17 Development Center for Biotechnology Alpha-enolase specific antibodies and methods of uses in cancer therapy
EP3193940A1 (en) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
CN113150147A (zh) * 2015-03-16 2021-07-23 塞尔德克斯医疗公司 抗-met抗体及其使用方法
KR102476846B1 (ko) * 2016-02-05 2022-12-12 주식회사 헬릭스미스 항―ｃ―ＭＥＴ 항체 및 이의 용도
EP3430058A4 (en) 2016-03-15 2019-10-23 Generon (Shanghai) Corporation Ltd. MULTISPECIFIC FAB FUSION PROTEINS AND USES THEREOF
SI3626273T1 (sl) 2016-05-17 2021-04-30 Abbvie Biotherapeutics Inc. Konjugati protitelesa proti CMET in zdravila ter postopki za njihovo uporabo
US10457726B2 (en) 2016-06-30 2019-10-29 University Of Connecticut Antibody and antigen-binding fragment compositions targeting cell surface antigens in tumors and methods of use thereof
EP3525829A1 (en) 2016-10-11 2019-08-21 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
WO2018088933A1 (en) * 2016-11-14 2018-05-17 Limited Liability Company "Panacela Labs" Anti-tumor effects of a viral vector encoding a toll-like receptor and a toll-like receptor agonist
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
US20180230218A1 (en) * 2017-01-04 2018-08-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
CN109771642B (zh) * 2017-11-13 2022-09-20 同济大学苏州研究院 c-MET激动型抗体及其用途
GB201803892D0 (en) * 2018-03-12 2018-04-25 Ultrahuman Six Ltd C-met binding agents
CA3098103A1 (en) 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
KR102835308B1 (ko) * 2018-08-08 2025-07-21 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질
EP3847196A4 (en) 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
CN109541221B (zh) * 2018-10-24 2022-03-22 益善生物技术股份有限公司 一种c-Met特异性抗体、组合物及试剂盒
KR102353568B1 (ko) 2018-11-14 2022-01-20 주식회사 헬릭스미스 안정성이 향상된 항 c-Met 항체 또는 그의 항원 결합 단편
WO2020132810A1 (en) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
US20220169706A1 (en) * 2019-03-28 2022-06-02 Danisco Us Inc Engineered antibodies
AU2020349462A1 (en) 2019-09-16 2022-03-03 Regeneron Pharmaceuticals, Inc. Radiolabeled MET binding proteins for immuno-PET imaging
EP4129335A4 (en) 2020-09-01 2024-04-24 RemeGen Co., Ltd. ANTI C-MET DRUG-ANTIBODY CONJUGATE AND ITS APPLICATIONS
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
BR112023020562A2 (pt) 2021-04-06 2023-12-05 Abbvie Biotherapeutics Inc Métodos de tratamento de carcinoma pulmonar de células não pequenas com o uso de telisotuzumabe vedotina
BR112023020801A2 (pt) * 2021-04-08 2023-12-12 Byondis Bv Anticorpo ou fragmento de ligação ao antígeno, conjugado anticorpo-fármaco, composição farmacêutica, e, combinação de um anticorpo ou fragmento de ligação ao antígeno, um conjugado anticorpo-fármaco ou uma composição farmacêutica
TW202547842A (zh) * 2021-04-29 2025-12-16 愛爾蘭商艾伯維製造管理無限公司 抗c-Met抗體藥物結合物
EP4426727A2 (en) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
WO2023173109A1 (en) 2022-03-11 2023-09-14 Abbvie Biotherapeutics Inc. Methods of treatment of non-small-cell lung carcinoma using telisotuzumab vedotin and osimertinib
WO2024243450A1 (en) 2023-05-23 2024-11-28 Abbvie Inc. Methods of treatment using anti-c-met antibody drug conjugates
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4424200A (en) 1979-05-14 1984-01-03 Nuc Med Inc. Method for radiolabeling proteins with technetium-99m
US4479930A (en) 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
KR100983997B1 (ko) * 2001-01-09 2010-09-28 메르크 파텐트 게엠베하 수용체 타이로신 키나아제 저해제 및 혈관형성 저해제를 사용하는 병용 요법
BRPI0407446A (pt) * 2003-02-13 2006-01-31 Pharmacia Corp Anticorpos para c-met para o tratamento de cânceres
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
CA2548282A1 (en) * 2003-12-11 2005-06-30 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
CA2575402A1 (en) 2004-08-05 2006-02-09 Genentech, Inc. Humanized anti-cmet antagonists
US8008443B2 (en) * 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
EP2397498A3 (en) * 2005-07-18 2013-11-27 Amgen, Inc Human anti-B7RP1 neutralizing antibodies
JP5457671B2 (ja) * 2005-07-28 2014-04-02 ノバルティス アーゲー Ｍ−ｃｓｆ特異的モノクローナル抗体およびその使用
US8101727B2 (en) * 2006-03-30 2012-01-24 Novartis Ag Compositions and methods of use for antibodies of c-Met
EP2014681A1 (en) * 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
US8545839B2 (en) 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody

Also Published As

Publication number Publication date
US8765128B2 (en) 2014-07-01
HK1162536A1 (zh) 2012-08-31
PT2370468T (pt) 2017-07-13
HUE035047T2 (en) 2018-05-02
US8747850B2 (en) 2014-06-10
US20110239316A1 (en) 2011-09-29
RU2011124751A (ru) 2013-01-10
SG187518A1 (en) 2013-02-28
US20130109844A1 (en) 2013-05-02
JP6074018B2 (ja) 2017-02-01
AU2016200725C1 (en) 2017-10-19
ES2827277T3 (es) 2021-05-20
EP3135691B1 (en) 2018-08-15
PL2370468T3 (pl) 2017-09-29
DK3135691T3 (en) 2018-11-19
CA2743433A1 (en) 2010-06-24
JP6309657B2 (ja) 2018-04-11
LT2370468T (lt) 2017-07-10
CN102227446B (zh) 2015-10-21
PL3135691T3 (pl) 2019-02-28
ES2697098T3 (es) 2019-01-22
BR122019023930B1 (pt) 2021-05-04
CL2014000181A1 (es) 2014-07-25
US8729249B2 (en) 2014-05-20
CA2743433C (en) 2019-06-11
BRPI0923231A2 (pt) 2016-01-26
JP5863458B2 (ja) 2016-02-16
PT3135691T (pt) 2018-11-27
JP2012510280A (ja) 2012-05-10
HRP20171011T8 (hr) 2019-01-25
IL213273A0 (en) 2011-07-31
JP2016117721A (ja) 2016-06-30
PE20120343A1 (es) 2012-04-16
US8741290B2 (en) 2014-06-03
TWI523866B (zh) 2016-03-01
AR074439A1 (es) 2011-01-19
TW201446805A (zh) 2014-12-16
US20130109841A1 (en) 2013-05-02
CY1121025T1 (el) 2019-12-11
MY185200A (en) 2021-04-30
DK2370468T3 (en) 2017-06-19
RU2015127471A (ru) 2018-12-21
HRP20171011T1 (hr) 2017-09-22
CN103351438B (zh) 2016-04-20
AU2009328318C1 (en) 2017-11-02
SI3431502T1 (sl) 2021-01-29
ECSP11011127A (es) 2011-07-29
TWI459964B (zh) 2014-11-11
MX341014B (es) 2016-08-03
CN102227446A (zh) 2011-10-26
AU2016200725A1 (en) 2016-02-25
SG171851A1 (en) 2011-07-28
TW201023892A (en) 2010-07-01
SI2370468T1 (sl) 2017-08-31
EP3431502A1 (en) 2019-01-23
TN2011000216A1 (en) 2012-12-17
CY1119172T1 (el) 2018-02-14
RU2560257C2 (ru) 2015-08-20
PT3431502T (pt) 2020-10-29
MX2011005677A (es) 2011-06-30
SA109300720B1 (ar) 2013-05-25
EP2370468A1 (en) 2011-10-05
EP3135691A1 (en) 2017-03-01
EP3757132A1 (en) 2020-12-30
LT3135691T (lt) 2018-11-12
KR20110097839A (ko) 2011-08-31
EP3431502B1 (en) 2020-07-22
CN103351438A (zh) 2013-10-16
RS58018B1 (sr) 2019-02-28
AU2009328318B2 (en) 2015-11-05
AU2017203929A1 (en) 2017-07-06
ZA201105164B (en) 2012-03-28
GEP20135930B (en) 2013-10-10
HRP20181868T1 (hr) 2019-01-11
SI3135691T1 (sl) 2018-12-31
CL2011001296A1 (es) 2011-08-26
JP2017099392A (ja) 2017-06-08
WO2010069765A1 (en) 2010-06-24
PH12015501515A1 (en) 2015-12-14
GEP20146207B (en) 2014-12-10
HK1190414A1 (zh) 2014-07-04
HUE040553T2 (hu) 2019-03-28
RS56204B1 (sr) 2017-11-30
KR101838299B1 (ko) 2018-03-14
MY192567A (en) 2022-08-29
CO6382139A2 (es) 2012-02-15
ES2629855T3 (es) 2017-08-16
AU2017203929B2 (en) 2019-03-28
IL231525B (en) 2019-07-31
CR20110324A (es) 2011-07-28
PL3431502T3 (pl) 2020-12-28
BRPI0923231B1 (pt) 2020-04-28
US20130109840A1 (en) 2013-05-02
EP2370468B1 (en) 2017-04-05
AU2009328318A1 (en) 2011-07-28
AU2016200725B2 (en) 2017-05-25
SA112331005B1 (ar) 2015-09-13
MA32892B1 (fr) 2011-12-01
HUE051288T2 (hu) 2021-03-01
IL231525A0 (en) 2014-04-30
NZ593853A (en) 2013-03-28

Similar Documents

Publication Publication Date Title
BRPI0923231B8 (pt) anticorpo anti-cmet
BR112014032999A2 (pt) optimização de anticorpos que ligam o gene de ativação de linfócito 3 (lag-3), e uso dos mesmos
BR112012001984B8 (pt) anticorpos humanos com alta afinidade para angiopoietina-2 humana, uso dos mesmos e composição farmacêutica
BR112014026952A2 (pt) derivados de aminopirimidina pirazol como moduladores lrrk2
BRPI0906404B8 (pt) construção de fusão com domínio lítico, seus usos, composição farmacêutica, bem como processo para reduzir ou inibir seletivamente a proliferação de uma célula que expressa um receptor, ligante ou antígeno
BR112013030958A2 (pt) "anticorpo que se liga ao fator de transformação de crescimento beta e seu uso no tratamento de câncer, fibrose e doenças associadas com expressão do referido fator, bem como molécula de ácido nucleico, vetor de expressão, célula hospedeira e seu método de uso para produzir anticorpo e composição farmacêutica".
BR112016027585A2 (pt) construções de anticorpo multiespecíficas
BR112015017548A8 (pt) construção de anticorpo multiespecífico isolado, sequência de ácido nucléico, vetor, célula hospedeira, processo para a produção da construção de anticorpo, composição farmaceutica, uso da construção de anticorpo e kit
BR112014011925A2 (pt) mutações no receptor notch humano e seu uso
BR112012026471A2 (pt) conjugado, processo para a síntese do mesmo, método para imagem de uma célula que expressa um transportador de neurotransmissor que compreende o contato da referida célula com o conjugado, processo para preparar um comporto de fórmula (ii) e (xiv) e composto
BR112012033406A2 (pt) anticorpo para diagnóstico e/ou prognóstico de câncer
BRPI0922350A2 (pt) anticorpo humano, mólecula biespecífica,vetor de expressão, célula hospedeira eucariótica ou procariótoca recombinante, composição farmacêutica, uso do anticorpo ou da molécula biespecífica, métodos para inibir o desenvolvimento e/ou proliferação de uma célula tumoral que expressa o fator de tecido, para produzir um anticorpo, e para detectar a presença de fator de tecido em uma amostra, composição de diagnóstico, e, kit para detectar a presença de fator de tecido em uma amostra.
BR112015003109A2 (pt) Composto, composição, uso de um composto, e, métodos para tratar ou prevenir um distúrbio, condição ou doença e para tratar diabetes mellitus tipo 2.
BR112014018561A8 (pt) Anticorpo; ácido nucleico; célula hospedeira; composição farmacêutica; uso de um anticorpo; método para produção de um anticorpo; e método para produção de uma linhagem celular que produz um anticorpo
TW201129378A (en) Materials and methods for treating or preventing HER-3 associated diseases
BRPI0808888B8 (pt) composto de fenil amino pirimidina para uso no tratamento de uma doença associada à quinase, processo para a preparação do composto, composição farmacêutica, e, implante
BR112018074869A2 (pt) anticorpos antagonistas que ligam t ao tgfb1, tgfb2 e ao tgfb3 humanos e seu uso para o tratamento de fibrose pulmonar
WO2012103165A3 (en) Anti-kit antibodies and uses thereof
BR112013019975A2 (pt) proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira"
BRPI0912475B8 (pt) compostos como inibidores de quinase, método para produção dos ditos compostos e composição farmacêutica
BR122021002201A8 (pt) Composto, composição, uso de um composto, e, método de tratamento de um distúrbio, condição ou doença
CO6620050A2 (es) Derivados de aminopirimidina como moduladores de la lrrk2
BR112015029788A2 (pt) hetero-multímero, construto de anticorpo isolado, ácido nucleico, célula hospedeira, método para preparar o hetero-multímero, composição farmacêutica, método para tratar uma doença, uso do hetero-multímero, uso de uma quantia terapêutica do hetero-multímero e método para reduzir a função efetora de um construto de anticorpo
UY32882A (es) (heteroarilmetil) tiohidantoínas sustituidas
CL2008002015A1 (es) Anticuerpo anti-receptor del factor de creciemiento de hepatocito (hgf)/receptor c-met; hibridoma que lo produce; acido nucleico que lo codifica; vector y celula huesped que los comprende; procedimiento de produccion; composicion que los comprende; su uso para tratar cancer; y metodo de diagnostico in vitro

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 28/04/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/12/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF